The inclusion of Empagliflozin could be a superior idea in treating patients with both diabetes and CKD in the early stages compared with other counterparts oral hypoglycemic agents like gliptins (DPP-4 inhibitors), owing to its potential ability to stimulate erythropoiesis and prevent the occurrence or progression of anaemia. The considerations that need to be considered while using Empagliflozin are genital infections and urinary tract infections. This has been a well-studied drug for many years and the results of various meta-analysis studies are a testament to the safety of this drug. The drug also prevents the progression of albuminuria and keeps serum creatinine levels in check and is also effective in treating diabetes in early-stage CKD patients. The multidimensional action of this drug in treating diabetes and its associated co-morbidity of anaemia in patients belonging to the described study population strongly indicates that the benefits of including this drug in their treatment could outweigh the risks associated with it. Instead of using antidiabetic drugs and oral iron supplements along with the therapy, using this could reduce the “pill burden” on the patient thus improving medication adherence. The potential of the drug to prevent renal damage and address other major complications associated with CKD as a package justifies why this study could be beneficial, which could give way to a more optimized therapy.